Overcoming Payer Barriers and Simplifying Treatment Through Patient Education in Tardive Dyskinesia

In 'Overcoming Payer Barriers and Simplifying Treatment Through Patient Education in Tardive Dyskinesia,' the expert psychiatry pharmacists examined the following critical questions:

What strategies can address payer-related barriers, such as cost and coverage, to facilitate treatment initiation?

What role does patient education play in simplifying perceived treatment complexities?

Led by the moderator, the panelists discussed strategies for addressing payer-related barriers to treatment initiation, including pursuing patient assistance programs, pre-adjudicating claims through specialty pharmacies, and pre-populating prior authorization forms with documentation of prior interventions such as anticholinergic discontinuation or trials of alternative agents. Jamie Kneebusch and Farah Khorassani noted that both vesicular monoamine transporter 2 (VMAT2) inhibitors are now available on Medicaid and Medicare formularies, though typically at a lower tier, and emphasized that manufacturers have committed to ensuring patients are not denied treatment due to cost. The panelists then explored the role of patient education in simplifying perceived treatment complexities, emphasizing the importance of thorough medication reconciliation, individualized counseling on timing and administration preferences, and setting realistic expectations around manageable side effects such as somnolence to support long-term adherence.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy,' features the panelists advancing their conversation on tardive dyskinesia and focusing on the role of the pharmacist in initiating and monitoring patients on VMAT2 inhibitors, as well as how specialty pharmacies can help identify patients suitable for VMAT2 therapy early in their disease course.